Molloy Anne M, Kirke Peadar N, Troendle James F, Burke Helen, Sutton Marie, Brody Lawrence C, Scott John M, Mills James L
Schools of Medicine, Trinity College Dublin, School of Medicine, Dublin 2, Ireland.
Pediatrics. 2009 Mar;123(3):917-23. doi: 10.1542/peds.2008-1173.
Folic acid fortification has reduced neural tube defect prevalence by 50% to 70%. It is unlikely that fortification levels will be increased to reduce neural tube defect prevalence further. Therefore, it is important to identify other modifiable risk factors. Vitamin B(12) is metabolically related to folate; moreover, previous studies have found low B(12) status in mothers of children affected by neural tube defect. Our objective was to quantify the effect of low B(12) status on neural tube defect risk in a high-prevalence, unfortified population.
We assessed pregnancy vitamin B(12) status concentrations in blood samples taken at an average of 15 weeks' gestation from 3 independent nested case-control groups of Irish women within population-based cohorts, at a time when vitamin supplementation or food fortification was rare. Group 1 blood samples were from 95 women during a neural tube defect-affected pregnancy and 265 control subjects. Group 2 included blood samples from 107 women who had a previous neural tube defect birth but whose current pregnancy was not affected and 414 control subjects. Group 3 samples were from 76 women during an affected pregnancy and 222 control subjects.
Mothers of children affected by neural tube defect had significantly lower B(12) status. In all 3 groups those in the lowest B(12) quartiles, compared with the highest, had between two and threefold higher adjusted odds ratios for being the mother of a child affected by neural tube defect. Pregnancy blood B(12) concentrations of <250 ng/L were associated with the highest risks.
Deficient or inadequate maternal vitamin B(12) status is associated with a significantly increased risk for neural tube defects. We suggest that women have vitamin B(12) levels of >300 ng/L (221 pmol/L) before becoming pregnant. Improving B(12) status beyond this level may afford a further reduction in risk, but this is uncertain.
叶酸强化已使神经管缺陷患病率降低了50%至70%。进一步提高强化水平以降低神经管缺陷患病率的可能性不大。因此,识别其他可改变的风险因素很重要。维生素B12在代谢上与叶酸相关;此外,先前的研究发现神经管缺陷患儿母亲的维生素B12水平较低。我们的目的是在一个高患病率、未进行强化的人群中,量化低维生素B12水平对神经管缺陷风险的影响。
我们评估了来自爱尔兰女性3个独立巢式病例对照研究组的孕妇血液样本中维生素B12的状态浓度,这些样本平均在妊娠15周时采集,来自基于人群的队列,当时很少有维生素补充或食物强化。第1组血液样本来自95名神经管缺陷患儿母亲和265名对照对象。第2组包括107名曾生育神经管缺陷患儿但当前妊娠未受影响的女性的血液样本和414名对照对象。第3组样本来自76名神经管缺陷患儿母亲和222名对照对象。
神经管缺陷患儿母亲的维生素B12水平显著较低。在所有3组中,维生素B12处于最低四分位数的母亲,与最高四分位数的母亲相比,生育神经管缺陷患儿的调整后比值比高出两到三倍。妊娠血液中维生素B12浓度<250 ng/L与最高风险相关。
母亲维生素B12水平不足或缺乏与神经管缺陷风险显著增加相关。我们建议女性在怀孕前维生素B12水平>300 ng/L(221 pmol/L)。将维生素B12水平提高到超过这一水平可能会进一步降低风险,但这并不确定。